ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
Research article published in Blood advances (2021)
Abstract
BACKGROUND: von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients. OBJECTIVE: These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD. METHODS: ASH, ISTH, NHF, and WFH formed a multidisciplinary guideline panel. Three patient representatives were included. The panel was balanced to minimize potential bias from conflicts of interest. The University of Kansas Outcomes and Implementation Research Unit and the McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing and updating systematic evidence reviews (through November 2019). The panel prioritized clinical questions and outcomes according to their importance to clinicians and patients. The panel used the GRADE approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 12 recommendations and outlined future research priorities. CONCLUSIONS: These guidelines make key recommendations regarding prophylaxis for frequent recurrent bleeding, desmopressin trials to determine therapy, use of antiplatelet agents and anticoagulant therapy, target VWF and factor VIII activity levels for major surgery, strategies to reduce bleeding during minor surgery or invasive procedures, management options for heavy menstrual bleeding, management of VWD in the context of neuraxial anesthesia during labor and delivery, and management in the postpartum setting.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients.
Warum dies für die Hirudotherapie relevant ist
Diese Leitlinie der American Society of Hematology (ASH), ISTH, NHF und WFH liefert 12 evidenzbasierte Empfehlungen zum Management der von-Willebrand-Erkrankung (VWD) und behandelt Prophylaxe, Desmopressin-Testungen, den Einsatz von Antikoagulanzien, das Management chirurgischer Blutungen sowie die Versorgung in der Schwangerschaft. Die Bezeichnung „ASH" im Titel bezieht sich auf die American Society of Hematology, nicht auf die American Society of Hirudotherapy. Das Abstract fokussiert ausschließlich auf konventionelle pharmakologische und Transfusionstherapien für eine Blutgerinnungsstörung. Es enthält keinerlei Erwähnung von Blutegeln, Hirudotherapie oder dem Egelsekretom; ihre Relevanz für die Hirudotherapie ist allenfalls als Hintergrundinformation einzustufen.
Zitation
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
Connell et al. · Blood advances, 2021
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026